Sensipar
Product Images NDC 68151-4740

6 FDA label images from Carilion Materials Management · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sensipar (NDC 68151-4740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl681514740)

Label Image (Lbl681514740)
Label for Sensipar 30 mg tablets featuring active ingredient cinacalcet HCl. Manufactured by Amgen, the label includes lot number 1040674, expiration date 06/14, and a barcode with product NDC 68151-4740. Marked as prescription only (RX only).*
FDA Label Image

Image 1 (Sensipar 1)

Image 1 (Sensipar 1)
Chemical structure of the active ingredient in Sensipar, showing a molecular diagram including a trifluoromethyl group (CF3) attached to a benzene ring, a secondary amine (NH) connected to a methyl-substituted indane structure, and a hydrochloride (HCl) moiety.*
FDA Label Image

Figure 1. (Sensipar 2)

Figure 1. (Sensipar 2)
A line graph comparing intact parathyroid hormone (iPTH) levels (pg/mL) over 26 weeks between Sensipar and placebo groups. The x-axis indicates time in weeks; the y-axis shows iPTH concentration. The Sensipar group line trends downward, while placebo remains relatively stable, with error bars on each data point.*
FDA Label Image

Figure 2. (Sensipar 3)

Figure 2. (Sensipar 3)
A line graph comparing Calcium-Phosphorus product levels (Ca x P, mg/dL) over 26 weeks between Sensipar and placebo. The x-axis shows weeks, and the y-axis shows Ca x P levels. Sensipar data are represented by a red line, showing a decrease followed by stabilization; placebo is shown by a black dashed line with relatively stable higher values.*
FDA Label Image

Figure 3. (Sensipar 4)

Figure 3. (Sensipar 4)
A line graph showing calcium levels (mg/dL) over weeks in parathyroid carcinoma patients. The x-axis represents time from baseline through titration and maintenance phases up to 80 weeks. The y-axis shows calcium concentrations ranging from 8 to 16 mg/dL. Data points with error bars illustrate calcium fluctuations across the study period.*
FDA Label Image

Figure 4. (Sensipar 5)

Figure 4. (Sensipar 5)
A line graph depicting calcium levels (mg/dL) over weeks for patients with intractable pHPT. The graph includes a titration phase and a maintenance phase, showing changes in calcium measurements across the study period with error bars at each data point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.